icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
kDBgA96mWL5vrF3A
Listen
